AI assistant
Lupin Ltd — Capital/Financing Update 2023
Nov 2, 2023
61031_rns_2023-11-02_0e749c4f-27d2-4d57-96d5-fe75d7c2bd26.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [79 x 93] intentionally omitted <==
November 2, 2023
BSE Limited
Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001.
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.
Dear Sir/Madam,
Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 (‘Listing Regulations’).
We are pleased to enclose a Press release regarding launch of Diazepam Rectal Gel, 10 mg and 20 mg, Rectal Delivery System, on receipt of approval for its ANDA from the U.S. FDA.
This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.
The above is for your information and dissemination.
Thanking you,
For LUPIN LIMITED
Rajvardhan Vishnu Satam
Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e2abcf 74700f5375b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726cdb6 7a2ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2023.11.02 15:49:32 +05'30'
R. V. SATAM COMPANY SECRETARY (ACS - 11973)
Encl: a/a
Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com
www.lupin.com
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN
Lupin Launches Diazepam Rectal Gel in the United States
Mumbai, Baltimore, November 02, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Diazepam Rectal Gel, 10 mg and 20 mg, Rectal Delivery System, after its wholly owned subsidiary, Novel Laboratories Inc., based in Somerset, New Jersey received an approval for its ANDA from the United States Food and Drug Administration (U.S. FDA).
Diazepam Rectal Gel, 10 mg and 20 mg, Rectal Delivery System is the generic version of Diastat® AcuDial[TM] Rectal Delivery System, 10 mg and 20 mg, of Bausch Health US, LLC.
Diazepam Rectal Gel (RLD Diastat® AcuDial[TM] ) had estimated annual sales of USD 37 million in the U.S. (IQVIA MAT September 2023).
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on:
Twitter: https://twitter.com/LupinGlobal|LinkedIn: https://www.linkedin.com/company/lupin Facebook: http://www.facebook.com/LupinWorld/
For further information or queries please contact –
Shweta Munjal
Vice President & Global Head – Corporate Communications & Sustainability Email: [email protected]
*Safe Harbor Statement
Diastat® AcuDial[TM] are registered trademarks of Bausch Health Companies Inc. or its affiliates.
Page 1 of 1